IL297741A - Treatment and/or prevention of a disease or syndrome associated with a viral infection - Google Patents

Info

Publication number

IL297741A

IL297741A IL297741A IL29774122A IL297741A IL 297741 A IL297741 A IL 297741A IL 297741 A IL297741 A IL 297741A IL 29774122 A IL29774122 A IL 29774122A IL 297741 A IL297741 A IL 297741A

Authority

IL

Israel

Prior art keywords

infection

aat

cov

sars

composition

Prior art date

2020-05-01

Links

• Espacenet
• Global Dossier
• Discuss

• 230000009385 viral infection Effects 0.000 title claims description 245
• 208000011580 syndromic disease Diseases 0.000 title claims description 114
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 91
• 201000010099 disease Diseases 0.000 title claims description 87
• 238000011282 treatment Methods 0.000 title claims description 79
• 230000002265 prevention Effects 0.000 title claims description 42
• 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 380
• 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 338
• 239000000203 mixture Substances 0.000 claims description 129
• 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 125
• 239000012634 fragment Substances 0.000 claims description 111
• 102000035195 Peptidases Human genes 0.000 claims description 104
• 108091005804 Peptidases Proteins 0.000 claims description 104
• 239000004365 Protease Substances 0.000 claims description 102
• 108010074328 Interferon-gamma Proteins 0.000 claims description 97
• 241001678559 COVID-19 virus Species 0.000 claims description 96
• 229940096437 Protein S Drugs 0.000 claims description 95
• 101710198474 Spike protein Proteins 0.000 claims description 95
• 108090000623 proteins and genes Proteins 0.000 claims description 85
• 208000024891 symptom Diseases 0.000 claims description 81
• 108010029485 Protein Isoforms Proteins 0.000 claims description 77
• 102000001708 Protein Isoforms Human genes 0.000 claims description 77
• 230000037452 priming Effects 0.000 claims description 77
• 238000000034 method Methods 0.000 claims description 74
• 102000004169 proteins and genes Human genes 0.000 claims description 72
• 102100037850 Interferon gamma Human genes 0.000 claims description 63
• 206010061218 Inflammation Diseases 0.000 claims description 61
• 102000005962 receptors Human genes 0.000 claims description 61
• 108020003175 receptors Proteins 0.000 claims description 61
• 230000004054 inflammatory process Effects 0.000 claims description 60
• 241000700605 Viruses Species 0.000 claims description 56
• 108090000624 Cathepsin L Proteins 0.000 claims description 38
• 102000004961 Furin Human genes 0.000 claims description 35
• 108090001126 Furin Proteins 0.000 claims description 35
• 102000008070 Interferon-gamma Human genes 0.000 claims description 34
• 229960003130 interferon gamma Drugs 0.000 claims description 34
• 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 31
• 208000015181 infectious disease Diseases 0.000 claims description 31
• 241000711573 Coronaviridae Species 0.000 claims description 29
• 102000004225 Cathepsin B Human genes 0.000 claims description 25
• 108090000712 Cathepsin B Proteins 0.000 claims description 25
• 208000027866 inflammatory disease Diseases 0.000 claims description 24
• 210000000653 nervous system Anatomy 0.000 claims description 23
• 108090000544 Proprotein convertase 1 Proteins 0.000 claims description 22
• 102000004142 Trypsin Human genes 0.000 claims description 22
• 108090000631 Trypsin Proteins 0.000 claims description 22
• 208000018737 Parkinson disease Diseases 0.000 claims description 21
• 239000012588 trypsin Substances 0.000 claims description 21
• 108010091175 Matriptase Proteins 0.000 claims description 20
• 208000024827 Alzheimer disease Diseases 0.000 claims description 19
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims description 19
• 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 19
• 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 19
• 239000002753 trypsin inhibitor Substances 0.000 claims description 19
• 201000006417 multiple sclerosis Diseases 0.000 claims description 15
• 230000000241 respiratory effect Effects 0.000 claims description 14
• 108010028275 Leukocyte Elastase Proteins 0.000 claims description 13
• 102000016799 Leukocyte elastase Human genes 0.000 claims description 13
• 210000004899 c-terminal region Anatomy 0.000 claims description 12
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 11
• 208000019423 liver disease Diseases 0.000 claims description 10
• 230000003115 biocidal effect Effects 0.000 claims description 8
• 206010012601 diabetes mellitus Diseases 0.000 claims description 8
• 230000002526 effect on cardiovascular system Effects 0.000 claims description 8
• 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 8
• 102000001189 Cyclic Peptides Human genes 0.000 claims description 7
• 108010069514 Cyclic Peptides Proteins 0.000 claims description 7
• 208000023105 Huntington disease Diseases 0.000 claims description 7
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 7
• 238000009472 formulation Methods 0.000 claims description 7
• 208000008589 Obesity Diseases 0.000 claims description 6
• 238000001415 gene therapy Methods 0.000 claims description 6
• 238000001802 infusion Methods 0.000 claims description 6
• 238000010253 intravenous injection Methods 0.000 claims description 6
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 6
• 239000002777 nucleoside Substances 0.000 claims description 6
• 150000003833 nucleoside derivatives Chemical class 0.000 claims description 6
• 235000020824 obesity Nutrition 0.000 claims description 6
• 108010005716 Interferon beta-1a Proteins 0.000 claims description 5
• 102000003996 Interferon-beta Human genes 0.000 claims description 5
• 108090000467 Interferon-beta Proteins 0.000 claims description 5
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
• 229960004461 interferon beta-1a Drugs 0.000 claims description 5
• 229960001388 interferon-beta Drugs 0.000 claims description 5
• 229950006348 sarilumab Drugs 0.000 claims description 5
• 229960003989 tocilizumab Drugs 0.000 claims description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 238000009169 immunotherapy Methods 0.000 claims description 4
• 238000001990 intravenous administration Methods 0.000 claims description 4
• 229960005486 vaccine Drugs 0.000 claims description 4
• 238000002659 cell therapy Methods 0.000 claims description 3
• 239000007933 dermal patch Substances 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 239000003889 eye drop Substances 0.000 claims description 3
• 229940012356 eye drops Drugs 0.000 claims description 3
• 239000007922 nasal spray Substances 0.000 claims description 3
• 229940097496 nasal spray Drugs 0.000 claims description 3
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
• 239000003242 anti bacterial agent Substances 0.000 claims description 2
• 230000007812 deficiency Effects 0.000 claims description 2
• 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 26
• 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims 10
• 101710081722 Antitrypsin Proteins 0.000 claims 2
• 102000004172 Cathepsin L Human genes 0.000 claims 2
• 102000004085 Proprotein convertase 1 Human genes 0.000 claims 2
• 230000001475 anti-trypsic effect Effects 0.000 claims 2
• 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 355
• 210000004027 cell Anatomy 0.000 description 241
• 208000025721 COVID-19 Diseases 0.000 description 197
• 208000037847 SARS-CoV-2-infection Diseases 0.000 description 179
• 208000001528 Coronaviridae Infections Diseases 0.000 description 174
• 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 115
• 235000019419 proteases Nutrition 0.000 description 76
• 235000018102 proteins Nutrition 0.000 description 65
• 108090000765 processed proteins & peptides Proteins 0.000 description 63
• 210000002381 plasma Anatomy 0.000 description 58
• 230000000694 effects Effects 0.000 description 52
• 239000013598 vector Substances 0.000 description 41
• 230000014509 gene expression Effects 0.000 description 40
• 235000001014 amino acid Nutrition 0.000 description 34
• 239000005089 Luciferase Substances 0.000 description 33
• 239000013612 plasmid Substances 0.000 description 33
• 102400001321 Cathepsin L Human genes 0.000 description 32
• 108060001084 Luciferase Proteins 0.000 description 32
• 150000001413 amino acids Chemical class 0.000 description 32
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
• 238000004519 manufacturing process Methods 0.000 description 26
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 25
• 239000002953 phosphate buffered saline Substances 0.000 description 25
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
• 239000000872 buffer Substances 0.000 description 23
• 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 22
• 239000000463 material Substances 0.000 description 22
• 102100032132 Neuroendocrine convertase 1 Human genes 0.000 description 21
• 238000002474 experimental method Methods 0.000 description 20
• 230000035772 mutation Effects 0.000 description 20
• 206010036790 Productive cough Diseases 0.000 description 19
• 230000007502 viral entry Effects 0.000 description 19
• 208000006820 Arthralgia Diseases 0.000 description 18
• 206010013975 Dyspnoeas Diseases 0.000 description 18
• 208000000112 Myalgia Diseases 0.000 description 18
• 241001112090 Pseudovirus Species 0.000 description 18
• 238000003556 assay Methods 0.000 description 18
• 230000003612 virological effect Effects 0.000 description 18
• 108020004414 DNA Proteins 0.000 description 17
• 230000001404 mediated effect Effects 0.000 description 17
• 108020004999 messenger RNA Proteins 0.000 description 17
• 102000004196 processed proteins & peptides Human genes 0.000 description 17
• 125000003275 alpha amino acid group Chemical group 0.000 description 15
• 238000001514 detection method Methods 0.000 description 15
• 239000011780 sodium chloride Substances 0.000 description 15
• 230000002401 inhibitory effect Effects 0.000 description 14
• 241000004176 Alphacoronavirus Species 0.000 description 13
• 230000004913 activation Effects 0.000 description 13
• 239000003814 drug Substances 0.000 description 13
• 230000005764 inhibitory process Effects 0.000 description 13
• 239000008194 pharmaceutical composition Substances 0.000 description 13
• 239000007983 Tris buffer Substances 0.000 description 12
• 210000000170 cell membrane Anatomy 0.000 description 12
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 12
• 239000003550 marker Substances 0.000 description 12
• 230000002829 reductive effect Effects 0.000 description 12
• 230000002441 reversible effect Effects 0.000 description 12
• 238000001890 transfection Methods 0.000 description 12
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 12
• 241000315672 SARS coronavirus Species 0.000 description 11
• 210000004072 lung Anatomy 0.000 description 11
• 239000006228 supernatant Substances 0.000 description 11
• 210000001519 tissue Anatomy 0.000 description 11
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
• -1 IL-14 Proteins 0.000 description 10
• 241000713666 Lentivirus Species 0.000 description 10
• 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 10
• 206010037660 Pyrexia Diseases 0.000 description 10
• 241001493065 dsRNA viruses Species 0.000 description 10
• 206010016256 fatigue Diseases 0.000 description 10
• 239000000047 product Substances 0.000 description 10
• 210000003802 sputum Anatomy 0.000 description 10
• 208000024794 sputum Diseases 0.000 description 10
• 238000010361 transduction Methods 0.000 description 10
• 230000026683 transduction Effects 0.000 description 10
• 206010011224 Cough Diseases 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 9
• 108090000695 Cytokines Proteins 0.000 description 9
• 206010012735 Diarrhoea Diseases 0.000 description 9
• 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 9
• 208000000059 Dyspnea Diseases 0.000 description 9
• 206010019233 Headaches Diseases 0.000 description 9
• 206010028813 Nausea Diseases 0.000 description 9
• 206010068319 Oropharyngeal pain Diseases 0.000 description 9
• 201000007100 Pharyngitis Diseases 0.000 description 9
• 238000011529 RT qPCR Methods 0.000 description 9
• 206010040744 Sinus headache Diseases 0.000 description 9
• 208000036142 Viral infection Diseases 0.000 description 9
• 206010047700 Vomiting Diseases 0.000 description 9
• 235000009697 arginine Nutrition 0.000 description 9
• 210000004556 brain Anatomy 0.000 description 9
• 239000003795 chemical substances by application Substances 0.000 description 9
• 230000006806 disease prevention Effects 0.000 description 9
• 231100000869 headache Toxicity 0.000 description 9
• 208000013465 muscle pain Diseases 0.000 description 9
• 230000008693 nausea Effects 0.000 description 9
• 230000004044 response Effects 0.000 description 9
• 230000008786 sensory perception of smell Effects 0.000 description 9
• 230000014860 sensory perception of taste Effects 0.000 description 9
• 229940124597 therapeutic agent Drugs 0.000 description 9
• 230000008673 vomiting Effects 0.000 description 9
• 108091007505 ADAM17 Proteins 0.000 description 8
• 108700028369 Alleles Proteins 0.000 description 8
• 241000588724 Escherichia coli Species 0.000 description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
• 102000016387 Pancreatic elastase Human genes 0.000 description 8
• 108010067372 Pancreatic elastase Proteins 0.000 description 8
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 230000003833 cell viability Effects 0.000 description 8
• 239000003153 chemical reaction reagent Substances 0.000 description 8
• 230000005284 excitation Effects 0.000 description 8
• 230000004927 fusion Effects 0.000 description 8
• 230000002068 genetic effect Effects 0.000 description 8
• 238000005259 measurement Methods 0.000 description 8
• 210000002161 motor neuron Anatomy 0.000 description 8
• 229920001184 polypeptide Polymers 0.000 description 8
• 230000000750 progressive effect Effects 0.000 description 8
• 239000013603 viral vector Substances 0.000 description 8
• 150000001875 compounds Chemical class 0.000 description 7
• 238000001476 gene delivery Methods 0.000 description 7
• 210000003494 hepatocyte Anatomy 0.000 description 7
• 210000005260 human cell Anatomy 0.000 description 7
• 108020004707 nucleic acids Proteins 0.000 description 7
• 102000039446 nucleic acids Human genes 0.000 description 7
• 150000007523 nucleic acids Chemical class 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• 241000494545 Cordyline virus 2 Species 0.000 description 6
• 241000709661 Enterovirus Species 0.000 description 6
• 206010044565 Tremor Diseases 0.000 description 6
• 238000009825 accumulation Methods 0.000 description 6
• 238000001042 affinity chromatography Methods 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 230000008499 blood brain barrier function Effects 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• 238000010367 cloning Methods 0.000 description 6
• 230000006378 damage Effects 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 150000004676 glycans Chemical class 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 239000003112 inhibitor Substances 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 239000002773 nucleotide Substances 0.000 description 6
• 238000011160 research Methods 0.000 description 6
• 238000012360 testing method Methods 0.000 description 6
• 241000701161 unidentified adenovirus Species 0.000 description 6
• 238000009423 ventilation Methods 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• IKQRPFTXKQQLJF-IAHYZSEUSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-n-(pyrrolidin-1-ylmethyl)-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound OC([C@@]1(O)C(=O)C=2[C@@H]([C@](C3=CC=CC(O)=C3C=2O)(C)O)C[C@H]1[C@@H](C1=O)N(C)C)=C1C(=O)NCN1CCCC1 IKQRPFTXKQQLJF-IAHYZSEUSA-N 0.000 description 5
• 206010000087 Abdominal pain upper Diseases 0.000 description 5
• 206010002942 Apathy Diseases 0.000 description 5
• 239000004475 Arginine Substances 0.000 description 5
• 241000008904 Betacoronavirus Species 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 206010008342 Cervix carcinoma Diseases 0.000 description 5
• 206010012289 Dementia Diseases 0.000 description 5
• 208000010201 Exanthema Diseases 0.000 description 5
• 206010025323 Lymphomas Diseases 0.000 description 5
• 206010035664 Pneumonia Diseases 0.000 description 5
• 208000032140 Sleepiness Diseases 0.000 description 5
• 206010041349 Somnolence Diseases 0.000 description 5
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 230000036528 appetite Effects 0.000 description 5
• 235000019789 appetite Nutrition 0.000 description 5
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• 201000010881 cervical cancer Diseases 0.000 description 5
• 238000003776 cleavage reaction Methods 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 239000003085 diluting agent Substances 0.000 description 5
• 210000000981 epithelium Anatomy 0.000 description 5
• 201000005884 exanthem Diseases 0.000 description 5
• 239000012091 fetal bovine serum Substances 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 239000001963 growth medium Substances 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 230000000670 limiting effect Effects 0.000 description 5
• 210000004185 liver Anatomy 0.000 description 5
• 208000020442 loss of weight Diseases 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 239000002609 medium Substances 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 230000001537 neural effect Effects 0.000 description 5
• 230000004770 neurodegeneration Effects 0.000 description 5
• 125000003729 nucleotide group Chemical group 0.000 description 5
• 230000036470 plasma concentration Effects 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 230000035755 proliferation Effects 0.000 description 5
• 206010037844 rash Diseases 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 239000011347 resin Substances 0.000 description 5
• 229920005989 resin Polymers 0.000 description 5
• 210000002345 respiratory system Anatomy 0.000 description 5
• 239000000523 sample Substances 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 239000003001 serine protease inhibitor Substances 0.000 description 5
• 231100000046 skin rash Toxicity 0.000 description 5
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
• 208000035143 Bacterial infection Diseases 0.000 description 4
• 241000124740 Bocaparvovirus Species 0.000 description 4
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
• 241000701022 Cytomegalovirus Species 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• 241001505332 Polyomavirus sp. Species 0.000 description 4
• 101150069374 Serpina1 gene Proteins 0.000 description 4
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
• 230000000840 anti-viral effect Effects 0.000 description 4
• 150000001484 arginines Chemical class 0.000 description 4
• 230000001363 autoimmune Effects 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 208000022362 bacterial infectious disease Diseases 0.000 description 4
• 210000001218 blood-brain barrier Anatomy 0.000 description 4
• 239000001110 calcium chloride Substances 0.000 description 4
• 235000011148 calcium chloride Nutrition 0.000 description 4
• 229910001628 calcium chloride Inorganic materials 0.000 description 4
• 230000010261 cell growth Effects 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 238000010276 construction Methods 0.000 description 4
• 239000013078 crystal Substances 0.000 description 4
• 206010052015 cytokine release syndrome Diseases 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 238000004520 electroporation Methods 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
• 210000001616 monocyte Anatomy 0.000 description 4
• 230000002018 overexpression Effects 0.000 description 4
• 102000040430 polynucleotide Human genes 0.000 description 4
• 108091033319 polynucleotide Proteins 0.000 description 4
• 239000002157 polynucleotide Substances 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 238000013268 sustained release Methods 0.000 description 4
• 239000012730 sustained-release form Substances 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
• IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 208000014644 Brain disease Diseases 0.000 description 3
• 108010012236 Chemokines Proteins 0.000 description 3
• 102000019034 Chemokines Human genes 0.000 description 3
• 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 3
• 102100031673 Corneodesmosin Human genes 0.000 description 3
• 101710139375 Corneodesmosin Proteins 0.000 description 3
• 206010050685 Cytokine storm Diseases 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 238000008157 ELISA kit Methods 0.000 description 3
• 206010014561 Emphysema Diseases 0.000 description 3
• 206010016207 Familial Mediterranean fever Diseases 0.000 description 3
• 208000005176 Hepatitis C Diseases 0.000 description 3
• 241000700586 Herpesviridae Species 0.000 description 3
• 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 3
• 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 3
• 244000309467 Human Coronavirus Species 0.000 description 3
• 241001428935 Human coronavirus OC43 Species 0.000 description 3
• 102000014150 Interferons Human genes 0.000 description 3
• 108010050904 Interferons Proteins 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• 208000004554 Leishmaniasis Diseases 0.000 description 3
• 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
• 241000351643 Metapneumovirus Species 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 208000002740 Muscle Rigidity Diseases 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 101710144127 Non-structural protein 1 Proteins 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
• 229920001213 Polysorbate 20 Polymers 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 241000700584 Simplexvirus Species 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 240000003768 Solanum lycopersicum Species 0.000 description 3
• 108010033576 Transferrin Receptors Proteins 0.000 description 3
• 102000007238 Transferrin Receptors Human genes 0.000 description 3
• 102100040247 Tumor necrosis factor Human genes 0.000 description 3
• 238000002835 absorbance Methods 0.000 description 3
• 208000038016 acute inflammation Diseases 0.000 description 3
• 230000006022 acute inflammation Effects 0.000 description 3
• 229960000723 ampicillin Drugs 0.000 description 3
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 230000007910 cell fusion Effects 0.000 description 3
• 208000037976 chronic inflammation Diseases 0.000 description 3
• 230000006020 chronic inflammation Effects 0.000 description 3
• 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 3
• 208000010877 cognitive disease Diseases 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 238000009295 crossflow filtration Methods 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• 239000012149 elution buffer Substances 0.000 description 3
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
• 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
• 239000013604 expression vector Substances 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• 102000037865 fusion proteins Human genes 0.000 description 3
• 108020001507 fusion proteins Proteins 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 208000010710 hepatitis C virus infection Diseases 0.000 description 3
• 102000048657 human ACE2 Human genes 0.000 description 3
• 210000002865 immune cell Anatomy 0.000 description 3
• 238000003018 immunoassay Methods 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000028709 inflammatory response Effects 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 229940079322 interferon Drugs 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 201000010901 lateral sclerosis Diseases 0.000 description 3
• 150000002632 lipids Chemical group 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 210000005265 lung cell Anatomy 0.000 description 3
• 230000006724 microglial activation Effects 0.000 description 3
• 230000002025 microglial effect Effects 0.000 description 3
• 239000002105 nanoparticle Substances 0.000 description 3
• 208000015122 neurodegenerative disease Diseases 0.000 description 3
• 238000010899 nucleation Methods 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
• 230000000644 propagated effect Effects 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 230000002797 proteolythic effect Effects 0.000 description 3
• 230000006337 proteolytic cleavage Effects 0.000 description 3
• 238000003753 real-time PCR Methods 0.000 description 3
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 229960005322 streptomycin Drugs 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 241000712461 unidentified influenza virus Species 0.000 description 3
• 230000005727 virus proliferation Effects 0.000 description 3
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
• 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
• 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 206010006100 Bradykinesia Diseases 0.000 description 2
• 102000005600 Cathepsins Human genes 0.000 description 2
• 108010084457 Cathepsins Proteins 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 208000028698 Cognitive impairment Diseases 0.000 description 2
• 108020004635 Complementary DNA Proteins 0.000 description 2
• 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• 101800001768 Exoribonuclease Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 101710114810 Glycoprotein Proteins 0.000 description 2
• 208000028782 Hereditary disease Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 241000711467 Human coronavirus 229E Species 0.000 description 2
• 241000482741 Human coronavirus NL63 Species 0.000 description 2
• 102000016252 Huntingtin Human genes 0.000 description 2
• 108050004784 Huntingtin Proteins 0.000 description 2
• 208000006083 Hypokinesia Diseases 0.000 description 2
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
• 102000003746 Insulin Receptor Human genes 0.000 description 2
• 108010001127 Insulin Receptor Proteins 0.000 description 2
• 102100034343 Integrase Human genes 0.000 description 2
• 101710104976 Interferon gamma-related Proteins 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 102000013462 Interleukin-12 Human genes 0.000 description 2
• 102000003810 Interleukin-18 Human genes 0.000 description 2
• 108090000171 Interleukin-18 Proteins 0.000 description 2
• 102100030703 Interleukin-22 Human genes 0.000 description 2
• 108010067003 Interleukin-33 Proteins 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 108090001007 Interleukin-8 Proteins 0.000 description 2
• 102100027612 Kallikrein-11 Human genes 0.000 description 2
• 239000006137 Luria-Bertani broth Substances 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 206010027374 Mental impairment Diseases 0.000 description 2
• 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 101800000510 Non-structural protein 7 Proteins 0.000 description 2
• 101800000509 Non-structural protein 8 Proteins 0.000 description 2
• YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 208000032319 Primary lateral sclerosis Diseases 0.000 description 2
• 108010048233 Procalcitonin Proteins 0.000 description 2
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
• 102000003923 Protein Kinase C Human genes 0.000 description 2
• 108090000315 Protein Kinase C Proteins 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 208000009341 RNA Virus Infections Diseases 0.000 description 2
• 238000002123 RNA extraction Methods 0.000 description 2
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
• 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 2
• 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 2
• 101800004575 RNA-directed RNA polymerase nsp12 Proteins 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 206010057190 Respiratory tract infections Diseases 0.000 description 2
• 108091028664 Ribonucleotide Proteins 0.000 description 2
• 241000724205 Rice stripe tenuivirus Species 0.000 description 2
• 102100031776 SH2 domain-containing protein 3A Human genes 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• 102000012479 Serine Proteases Human genes 0.000 description 2
• 108010022999 Serine Proteases Proteins 0.000 description 2
• 102000008847 Serpin Human genes 0.000 description 2
• 108050000761 Serpin Proteins 0.000 description 2
• 101710167605 Spike glycoprotein Proteins 0.000 description 2
• 101710172711 Structural protein Proteins 0.000 description 2
• RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• 102000004338 Transferrin Human genes 0.000 description 2
• 108090000901 Transferrin Proteins 0.000 description 2
• 229920004890 Triton X-100 Polymers 0.000 description 2
• 101710152431 Trypsin-like protease Proteins 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
• 108010067390 Viral Proteins Proteins 0.000 description 2
• 101150054399 ace2 gene Proteins 0.000 description 2
• 101150063416 add gene Proteins 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 108010079279 alpha 1-antitrypsin Portland Proteins 0.000 description 2
• 238000005571 anion exchange chromatography Methods 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
• 238000003149 assay kit Methods 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 238000012575 bio-layer interferometry Methods 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 229960000074 biopharmaceutical Drugs 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 229930189065 blasticidin Natural products 0.000 description 2
• OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 2
• 229960003870 bromhexine Drugs 0.000 description 2
• 210000004900 c-terminal fragment Anatomy 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• XASIMHXSUQUHLV-UHFFFAOYSA-N camostat Chemical compound C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 XASIMHXSUQUHLV-UHFFFAOYSA-N 0.000 description 2
• 229960000772 camostat Drugs 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 229960003677 chloroquine Drugs 0.000 description 2
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 208000019425 cirrhosis of liver Diseases 0.000 description 2
• 238000013377 clone selection method Methods 0.000 description 2
• 238000012790 confirmation Methods 0.000 description 2
• 230000000875 corresponding effect Effects 0.000 description 2
• 239000012228 culture supernatant Substances 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000003412 degenerative effect Effects 0.000 description 2
• 239000005547 deoxyribonucleotide Substances 0.000 description 2
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 201000002491 encephalomyelitis Diseases 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 239000003797 essential amino acid Substances 0.000 description 2
• 235000020776 essential amino acid Nutrition 0.000 description 2
• CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
• 229960004171 hydroxychloroquine Drugs 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 238000002595 magnetic resonance imaging Methods 0.000 description 2
• KJLLKLRVCJAFRY-UHFFFAOYSA-N mebutizide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(C(C)C(C)CC)NC2=C1 KJLLKLRVCJAFRY-UHFFFAOYSA-N 0.000 description 2
• 208000005264 motor neuron disease Diseases 0.000 description 2
• 210000000822 natural killer cell Anatomy 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 230000016273 neuron death Effects 0.000 description 2
• 238000002640 oxygen therapy Methods 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
• 230000001144 postural effect Effects 0.000 description 2
• 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 2
• CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 2
• 201000008752 progressive muscular atrophy Diseases 0.000 description 2
• 230000001915 proofreading effect Effects 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 239000008213 purified water Substances 0.000 description 2
• 229950010131 puromycin Drugs 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 239000002336 ribonucleotide Substances 0.000 description 2
• 125000002652 ribonucleotide group Chemical group 0.000 description 2
• 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
• 239000000779 smoke Substances 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 241000114864 ssRNA viruses Species 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 239000012581 transferrin Substances 0.000 description 2
• 238000003146 transient transfection Methods 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 230000005951 type IV hypersensitivity Effects 0.000 description 2
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 238000010200 validation analysis Methods 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 230000007501 viral attachment Effects 0.000 description 2
• OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
• BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
• UHEPSJJJMTWUCP-DHDYTCSHSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-DHDYTCSHSA-N 0.000 description 1
• AMFDITJFBUXZQN-KUBHLMPHSA-N (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound C=1NC=2C(N)=NC=NC=2C=1[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O AMFDITJFBUXZQN-KUBHLMPHSA-N 0.000 description 1
• GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
• TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
• 101150055869 25 gene Proteins 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
• WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
• 208000000187 Abnormal Reflex Diseases 0.000 description 1
• 208000020053 Abnormal inflammatory response Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 208000006888 Agnosia Diseases 0.000 description 1
• 102100027211 Albumin Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 208000037259 Amyloid Plaque Diseases 0.000 description 1
• 206010002027 Amyotrophy Diseases 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 206010003062 Apraxia Diseases 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 206010069632 Bladder dysfunction Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108050006947 CXC Chemokine Proteins 0.000 description 1
• 102000019388 CXC chemokine Human genes 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 102000001327 Chemokine CCL5 Human genes 0.000 description 1
• 108010055166 Chemokine CCL5 Proteins 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 206010009848 Cogwheel rigidity Diseases 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 208000004449 DNA Virus Infections Diseases 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 238000011238 DNA vaccination Methods 0.000 description 1
• GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
• 208000019505 Deglutition disease Diseases 0.000 description 1
• 241001461743 Deltacoronavirus Species 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
• 206010013887 Dysarthria Diseases 0.000 description 1
• 206010013976 Dyspraxia Diseases 0.000 description 1
• 208000014094 Dystonic disease Diseases 0.000 description 1
• 239000001692 EU approved anti-caking agent Substances 0.000 description 1
• 102000016942 Elastin Human genes 0.000 description 1
• 108010014258 Elastin Proteins 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 101001039702 Escherichia coli (strain K12) Methyl-accepting chemotaxis protein I Proteins 0.000 description 1
• 108700039887 Essential Genes Proteins 0.000 description 1
• 208000001308 Fasciculation Diseases 0.000 description 1
• 208000004930 Fatty Liver Diseases 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 241000710781 Flaviviridae Species 0.000 description 1
• 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 241000008920 Gammacoronavirus Species 0.000 description 1
• 101150112014 Gapdh gene Proteins 0.000 description 1
• 241000963438 Gaussia <copepod> Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 229940122604 HCV protease inhibitor Drugs 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 229940122440 HIV protease inhibitor Drugs 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
• 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 1
• 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 1
• 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 1
• 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 1
• 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 1
• 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 description 1
• 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 1
• 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
• 101150043003 Htt gene Proteins 0.000 description 1
• 101000756400 Human T-cell leukemia virus 2 Protein Rex Proteins 0.000 description 1
• 241001109669 Human coronavirus HKU1 Species 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010020591 Hypercapnia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000014429 Insulin-like growth factor Human genes 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 102000003814 Interleukin-10 Human genes 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 102000003815 Interleukin-11 Human genes 0.000 description 1
• 108090000176 Interleukin-13 Proteins 0.000 description 1
• 108090000172 Interleukin-15 Proteins 0.000 description 1
• 101800003050 Interleukin-16 Proteins 0.000 description 1
• 102000013691 Interleukin-17 Human genes 0.000 description 1
• 108050003558 Interleukin-17 Proteins 0.000 description 1
• 108050009288 Interleukin-19 Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
• 108010065637 Interleukin-23 Proteins 0.000 description 1
• 108010066979 Interleukin-27 Proteins 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 108091007973 Interleukin-36 Proteins 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• SXTAYKAGBXMACB-DPVSGNNYSA-N L-methionine sulfoximine Chemical compound CS(=N)(=O)CC[C@H](N)C(O)=O SXTAYKAGBXMACB-DPVSGNNYSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 102000007330 LDL Lipoproteins Human genes 0.000 description 1
• 108010007622 LDL Lipoproteins Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 206010067125 Liver injury Diseases 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 239000006142 Luria-Bertani Agar Substances 0.000 description 1
• 101000577064 Lymnaea stagnalis Molluscan insulin-related peptide 1 Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• 208000027382 Mental deterioration Diseases 0.000 description 1
• 108060004795 Methyltransferase Proteins 0.000 description 1
• HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 206010028293 Muscle contractions involuntary Diseases 0.000 description 1
• 206010062575 Muscle contracture Diseases 0.000 description 1
• 235000021360 Myristic acid Nutrition 0.000 description 1
• TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
• 101000737895 Mytilus edulis Contraction-inhibiting peptide 1 Proteins 0.000 description 1
• XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 description 1
• OFKKPUNNTZKBSR-VIFPVBQESA-N N(6)-(2,4-dinitrophenyl)-L-lysine Chemical compound OC(=O)[C@@H](N)CCCCNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OFKKPUNNTZKBSR-VIFPVBQESA-N 0.000 description 1
• 230000006051 NK cell activation Effects 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
• 206010060860 Neurological symptom Diseases 0.000 description 1
• 101800000935 Non-structural protein 12 Proteins 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 101150001779 ORF1a gene Proteins 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 206010053159 Organ failure Diseases 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• 238000009004 PCR Kit Methods 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 239000002033 PVDF binder Substances 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 208000027089 Parkinsonian disease Diseases 0.000 description 1
• 206010034010 Parkinsonism Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 206010035737 Pneumonia viral Diseases 0.000 description 1
• 206010067206 Postural reflex impairment Diseases 0.000 description 1
• 238000010806 PrimeScriptTM RT Reagent kit Methods 0.000 description 1
• 206010053395 Progressive multiple sclerosis Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 102000029301 Protein S Human genes 0.000 description 1
• 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
• 102000044437 S1 domains Human genes 0.000 description 1
• 108700036684 S1 domains Proteins 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 101500025257 Severe acute respiratory syndrome coronavirus 2 RNA-directed RNA polymerase nsp12 Proteins 0.000 description 1
• 201000001880 Sexual dysfunction Diseases 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 208000014604 Specific Language disease Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 241000187747 Streptomyces Species 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 101150057615 Syn gene Proteins 0.000 description 1
• 206010071436 Systolic dysfunction Diseases 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 206010057040 Temperature intolerance Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 102100032452 Transmembrane protease serine 6 Human genes 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
• 208000012886 Vertigo Diseases 0.000 description 1
• 108700010756 Viral Polyproteins Proteins 0.000 description 1
• 108020000999 Viral RNA Proteins 0.000 description 1
• 108070000030 Viral receptors Proteins 0.000 description 1
• 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
• 101150037054 aat gene Proteins 0.000 description 1
• 230000004598 abnormal eye movement Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 229960004150 aciclovir Drugs 0.000 description 1
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 206010000891 acute myocardial infarction Diseases 0.000 description 1
• 230000009218 additive inhibitory effect Effects 0.000 description 1
• 108010016828 adenylyl sulfate-ammonia adenylyltransferase Proteins 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 210000001552 airway epithelial cell Anatomy 0.000 description 1
• 210000001132 alveolar macrophage Anatomy 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000001775 anti-pathogenic effect Effects 0.000 description 1
• 239000012984 antibiotic solution Substances 0.000 description 1
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 201000007201 aphasia Diseases 0.000 description 1
• 230000025194 apoptotic cell clearance Effects 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 231100000877 autonomic nervous system dysfunction Toxicity 0.000 description 1
• 238000011888 autopsy Methods 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 210000004227 basal ganglia Anatomy 0.000 description 1
• 231100000871 behavioral problem Toxicity 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 239000012888 bovine serum Substances 0.000 description 1
• 201000007637 bowel dysfunction Diseases 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 238000004422 calculation algorithm Methods 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 229960003669 carbenicillin Drugs 0.000 description 1
• FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 230000001055 chewing effect Effects 0.000 description 1
• BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
• 208000012601 choreatic disease Diseases 0.000 description 1
• 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• 230000027288 circadian rhythm Effects 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 238000012761 co-transfection Methods 0.000 description 1
• 238000011278 co-treatment Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000002301 combined effect Effects 0.000 description 1
• 208000030251 communication disease Diseases 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 208000006111 contracture Diseases 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 230000003291 dopaminomimetic effect Effects 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 208000010118 dystonia Diseases 0.000 description 1
• 229920002549 elastin Polymers 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000008753 endothelial function Effects 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 239000006167 equilibration buffer Substances 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 229940073505 ethyl vanillin Drugs 0.000 description 1
• 210000001808 exosome Anatomy 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 230000008921 facial expression Effects 0.000 description 1
• 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 230000033581 fucosylation Effects 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
• 229940035482 glassia Drugs 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 230000008543 heat sensitivity Effects 0.000 description 1
• 230000002324 hematogenic effect Effects 0.000 description 1
• 231100000753 hepatic injury Toxicity 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 230000003118 histopathologic effect Effects 0.000 description 1
• 102000052502 human ELANE Human genes 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 206010020745 hyperreflexia Diseases 0.000 description 1
• 230000035859 hyperreflexia Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 230000005022 impaired gait Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 108090000681 interleukin 20 Proteins 0.000 description 1
• 229940046732 interleukin inhibitors Drugs 0.000 description 1
• 230000004073 interleukin-2 production Effects 0.000 description 1
• 108010074108 interleukin-21 Proteins 0.000 description 1
• 108010074109 interleukin-22 Proteins 0.000 description 1
• 108090000237 interleukin-24 Proteins 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 208000018883 loss of balance Diseases 0.000 description 1
• 231100000863 loss of memory Toxicity 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 230000004199 lung function Effects 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 210000003712 lysosome Anatomy 0.000 description 1
• 230000001868 lysosomic effect Effects 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 108010047374 matriptase 2 Proteins 0.000 description 1
• 230000004630 mental health Effects 0.000 description 1
• 230000006996 mental state Effects 0.000 description 1
• CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 1
• 210000000274 microglia Anatomy 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 229950000844 mizoribine Drugs 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• MQUQNUAYKLCRME-UHFFFAOYSA-N n-(4-chloro-3-oxo-1-phenylbutan-2-yl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-UHFFFAOYSA-N 0.000 description 1
• 230000007107 neurocognitive deficit Effects 0.000 description 1
• 230000003959 neuroinflammation Effects 0.000 description 1
• 230000003557 neuropsychological effect Effects 0.000 description 1
• 230000002276 neurotropic effect Effects 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 230000011242 neutrophil chemotaxis Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 201000001909 oculomotor nerve paralysis Diseases 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 229940090668 parachlorophenol Drugs 0.000 description 1
• 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
• 230000007918 pathogenicity Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 238000000053 physical method Methods 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
• 108010040003 polyglutamine Proteins 0.000 description 1
• 229920000155 polyglutamine Polymers 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 201000002241 progressive bulbar palsy Diseases 0.000 description 1
• 208000026526 progressive weakness Diseases 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 239000000473 propyl gallate Substances 0.000 description 1
• 229940075579 propyl gallate Drugs 0.000 description 1
• 235000010388 propyl gallate Nutrition 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 229940126731 protein tyrosine phosphatase inhibitor Drugs 0.000 description 1
• 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
• 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
• 239000012264 purified product Substances 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
• 238000009790 rate-determining step (RDS) Methods 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 239000012557 regeneration buffer Substances 0.000 description 1
• RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
• RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
• QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 230000004202 respiratory function Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 229960000329 ribavirin Drugs 0.000 description 1
• HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
• 229920002477 rna polymer Polymers 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 238000011012 sanitization Methods 0.000 description 1
• 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 231100000872 sexual dysfunction Toxicity 0.000 description 1
• 238000012807 shake-flask culturing Methods 0.000 description 1
• 230000009450 sialylation Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 230000007958 sleep Effects 0.000 description 1
• 230000004599 slow eye movement Effects 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000007863 steatosis Effects 0.000 description 1
• 231100000240 steatosis hepatitis Toxicity 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 210000003523 substantia nigra Anatomy 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 229940044609 sulfur dioxide Drugs 0.000 description 1
• 235000010269 sulphur dioxide Nutrition 0.000 description 1
• 230000009469 supplementation Effects 0.000 description 1
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 210000002820 sympathetic nervous system Anatomy 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 230000008791 toxic response Effects 0.000 description 1
• 230000031998 transcytosis Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 230000010415 tropism Effects 0.000 description 1
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
• 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
• 230000006433 tumor necrosis factor production Effects 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 238000012795 verification Methods 0.000 description 1
• 231100000889 vertigo Toxicity 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 208000009421 viral pneumonia Diseases 0.000 description 1
• 230000006490 viral transcription Effects 0.000 description 1
• 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1